Diasorin & Thermo Fisher Sign Exclusive U.S. Distribution Deal — A Major Move in Rapid Molecular POC Expansion

## **🔍 Diasorin & Thermo Fisher Sign Exclusive U.S. Distribution Deal — A Major Move in Rapid Molecular POC Expansion** Diasorin has entered an **exclusive U.S. hospital‑channel distribution agreement** with Fisher Scientific (Thermo Fisher Scientific) to commercialize the **Liaison NES rapid molecular point‑of‑care system**, following its recent **FDA 510(k) clearance and CLIA waiver** for the 15‑minute Flu A/B, RSV, and SARS‑CoV‑2 panel. The partnership immediately strengthens Diasorin’s reach across **7,000+ U.S. hospitals** and sets the stage for additional agreements targeting the **130,000‑site physician office lab (POL) market**. --- # **📌 Key Highlights from the Press Release** ### **1. Exclusive U.S. Hospital Distribution via Thermo Fisher** - Fisher Scientific will distribute the **Liaison NES** platform across U.S. hospitals. - This accelerates Diasorin’s penetration into large **Integrated Delivery Networks (IDNs)**. ### **2. Recently Cleared 4‑Plex Respiratory Panel** - Detects **Flu A, Flu B, RSV, and SARS‑CoV‑2**. - Delivers **PCR‑quality results in ~15 minutes** using a **simple three‑step workflow**. ### **3. Expansion Beyond Hospitals** - Diasorin is finalizing additional distribution agreements to reach the **non‑acute POL segment** (130,000+ sites). - NES is positioned to compete with other sub‑20‑minute molecular systems like **bioMérieux SpotFire** and **Nuclein Dash**. ### **4. Strengthened U.S. Commercial Footprint** - Diasorin has expanded its dedicated NES salesforce. - Thermo Fisher’s footprint complements Diasorin’s existing MDX and PLEX molecular portfolio. --- # **📈 What This Means for the POC Molecular Market** This agreement signals a **major competitive escalation** in rapid molecular diagnostics: - NES now has **immediate access** to the largest hospital distribution network in the U.S. - The combination of **CLIA waiver + rapid PCR + strong channel partners** positions NES as a credible challenger to incumbents like Cepheid, Abbott, Roche, and BD. - The push into **POLs and decentralized care** aligns with broader market shifts toward near‑patient molecular testing. --- # **📘 GRN IVD Consulting — Your Strategic Lens on the POC Market** The Diasorin–Thermo Fisher partnership underscores exactly why diagnostics companies, investors, and BD teams need **clear, data‑driven insight** into the evolving POC landscape. The **GRN IVD Consulting Point‑of‑Care Market Report** provides: - **Market sizing & growth forecasts** across respiratory, molecular, and decentralized testing segments - **Competitive intelligence** on platforms like NES, ID NOW, Liat, GeneXpert Xpress, SpotFire, Dash, and more - **Channel strategy analysis** (hospital, retail, POL, urgent care) - **Workflow, menu, and regulatory comparisons** across leading POC systems - **Actionable recommendations** for commercial, BD, and investment teams If your organization needs to understand **where POC molecular is heading and how to position for growth**, this report delivers the clarity and strategic depth required. Download our Point-of-Care Market Report or contact us to tailor insights for your 2026 planning.